Literature DB >> 2703529

Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis.

E Cantrill1, M Murray, I Mehta, G C Farrell.   

Abstract

Elevated serum estradiol concentrations and specific changes in the biliary excretion of some androstenedione metabolites have been reported in male rats with portal bypass produced by portal vein ligation (PVL). In this study, the hypothesis that male-specific forms of cytochrome P-450 are altered after PVL was tested by measuring microsomal steroid hydroxylase activities. Consistent with earlier findings in the intact animal, androstenedione 16 alpha-hydroxylase activity was reduced after PVL to 44% of control (P less than 0.05). Other pathways of androstenedione hydroxylation, and total estrogen formation (after androstenedione aromatization) were unchanged. Although total estrogen formation was not different, a sevenfold greater proportion of estradiol was produced in PVL rat microsomes. Additional experiments revealed that PVL selectively reduced the rate of microsomal estradiol 16 alpha-hydroxylation (to 56% of control, P less than 0.02). Levels of cytochrome P-450UT-A, the microsomal steroid 16 alpha-hydroxylase, were lower after PVL (56% of control, P less than 0.05), so that the present observations are consistent with the earlier suggestion that portal bypass is associated with the selective downregulation of this enzyme. Since downregulation of cytochrome P-450UT-A also occurs in experimental hepatic cirrhosis, portal hypertension may well contribute significantly to altered drug metabolism in liver disease. Impaired hepatic elimination of androstenedione by hydroxylation may indirectly enhance extrahepatic aromatization of the androgen. The decreased activity of hepatic estradiol 16 alpha-hydroxylation after PVL would enhance the accumulation of estradiol, the biologically more potent estrogen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703529      PMCID: PMC303809          DOI: 10.1172/JCI114003

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Sex difference in rate of ring A reduction of delta 4-3-keto-steroids in vitro by rat liver.

Authors:  F E YATES; A L HERBST; J URQUHART
Journal:  Endocrinology       Date:  1958-12       Impact factor: 4.736

2.  Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity.

Authors:  B H Lauterburg; V Sautter; R Preisig; J Bircher
Journal:  Gastroenterology       Date:  1976-08       Impact factor: 22.682

3.  Neonatal imprinting of liver microsomal hydroxylation and reduction of steroids.

Authors:  K Einarsson; J A Gustafsson; A Stenberg
Journal:  J Biol Chem       Date:  1973-07-25       Impact factor: 5.157

4.  Microsomal 17beta-hydroxysteroid dehydrogenase of guinea pig liver: detergent solubilization and a comparison of kinetic and stability properties of bound and solubilized forms.

Authors:  C H Blomquist; C E Kotts; E Y Hakanson
Journal:  J Steroid Biochem       Date:  1977-03       Impact factor: 4.292

5.  Reduced serum somatomedin activity in patients with chronic liver disease.

Authors:  A Wu; D B Grant; J Hambley; A J Levi
Journal:  Clin Sci Mol Med       Date:  1974-10

6.  Monoclonal antibodies inhibitory to rat hepatic cytochromes P-450: P-450 form specificities and use as probes for cytochrome P-450-dependent steroid hydroxylations.

Authors:  D J Waxman; D P Lapenson; S S Park; C Attisano; H V Gelboin
Journal:  Mol Pharmacol       Date:  1987-11       Impact factor: 4.436

7.  Selective reactivation of steroid hydroxylases following dissociation of the isosafrole metabolite complex with rat hepatic cytochrome P-450.

Authors:  M Murray; L Zaluzny; G C Farrell
Journal:  Arch Biochem Biophys       Date:  1986-12       Impact factor: 4.013

8.  Impaired androgen 16 alpha-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats.

Authors:  M Murray; L Zaluzny; G C Farrell
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

9.  Suppression of levels of phenobarbital-inducible rat liver cytochrome P-450 by pituitary hormone.

Authors:  Y Yamazoe; M Shimada; N Murayama; R Kato
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

10.  Metabolic clearance of human growth hormone in patients with hepatic and renal failure, and in the isolated perfused pig liver.

Authors:  D P Cameron; H G Burger; K J Catt; E Gordon; J M Watts
Journal:  Metabolism       Date:  1972-10       Impact factor: 8.694

View more
  5 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Differential regulation of endobiotic-oxidizing cytochromes P450 in vitamin A-deficient male rat liver.

Authors:  M Murray; R M Sefton; K D Croft; A M Butler
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.

Authors:  Michael Murray; Tina B Gillani; Tristan Rawling; Pramod C Nair
Journal:  AAPS J       Date:  2019-10-21       Impact factor: 4.009

4.  The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.

Authors:  Stanton Tam; Yassir Al-Zubaidi; Md Khalilur Rahman; Kirsi Bourget; Fanfan Zhou; Michael Murray
Journal:  Pharmacol Rep       Date:  2022-07-30       Impact factor: 3.919

Review 5.  P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.

Authors:  M Murray
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.